Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
|Articles|January 3, 2019
- Dermatology Times, January 2019 (Vol. 40, No. 1)
- Volume 40
- Issue 1
AAD annual meeting starts March 1
Author(s)Dermatology Times Staff
The American Academy of Dermatology annual meeting will be held from March 1-5 in Washington, D.C.
Advertisement
Early bird registration for the American Academy of Dermatology annual meeting closes January 23. Advance registration will run through February 20 for the meeting which runs March 1-5 in Washington, D.C.
For more information about the meeting, visit:
Articles in this issue
almost 8 years ago
Medicare physician fee schedule changesalmost 8 years ago
Access to dermatologic care varies by demographicalmost 8 years ago
Digital tools impact daily dermatology practicealmost 8 years ago
AAD updates cutaneous melanoma guidelinesalmost 8 years ago
Artificial Intelligence. Friend or foe of dermatology?almost 8 years ago
Improving the reporting of social media recruitment for clinical trialsalmost 8 years ago
Warning signs of life-threatening purpuraalmost 8 years ago
Optimize clinical trial recruitment with digital platformsalmost 8 years ago
Digital health and dermatologyalmost 8 years ago
The future of dermatologyAdvertisement
Related to this article
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Advertisement
Advertisement